- Home
- PHAR vs QSI Comparison
PHAR vs QSI Comparison
Compare PHAR & QSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- QSI
- Stock Information
- Founded
- PHAR 1988
- QSI 2013
- Country
- PHAR Netherlands
- QSI United States
- Employees
- PHAR N/A
- QSI N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- QSI Biotechnology: Pharmaceutical Preparations
- Sector
- PHAR Health Care
- QSI Health Care
- Exchange
- PHAR Nasdaq
- QSI Nasdaq
- Market Cap
- PHAR 731.1M
- QSI 334.9M
- IPO Year
- PHAR N/A
- QSI N/A
- Fundamental
- Price
- PHAR $10.42
- QSI $1.71
- Analyst Decision
- PHAR Strong Buy
- QSI Strong Buy
- Analyst Count
- PHAR 3
- QSI 3
- Target Price
- PHAR $30.00
- QSI $2.38
- AVG Volume (30 Days)
- PHAR 3.5K
- QSI 8.7M
- Earning Date
- PHAR 07-31-2025
- QSI 08-05-2025
- Dividend Yield
- PHAR N/A
- QSI N/A
- EPS Growth
- PHAR N/A
- QSI N/A
- EPS
- PHAR N/A
- QSI N/A
- Revenue
- PHAR $320,708,000.00
- QSI $3,443,000.00
- Revenue This Year
- PHAR $13.31
- QSI $77.57
- Revenue Next Year
- PHAR $7.68
- QSI $251.34
- P/E Ratio
- PHAR N/A
- QSI N/A
- Revenue Growth
- PHAR 24.13
- QSI 167.94
- 52 Week Low
- PHAR $6.65
- QSI $0.61
- 52 Week High
- PHAR $12.61
- QSI $5.77
- Technical
- Relative Strength Index (RSI)
- PHAR 48.06
- QSI 45.67
- Support Level
- PHAR $9.99
- QSI $1.67
- Resistance Level
- PHAR $10.49
- QSI $1.89
- Average True Range (ATR)
- PHAR 0.33
- QSI 0.12
- MACD
- PHAR -0.11
- QSI -0.04
- Stochastic Oscillator
- PHAR 29.19
- QSI 5.88
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.